plasma cell cancer

Melieva 2mg Tablet: Targeted Alkylating Therapy for Multiple Myeloma and Advanced Malignancies Are you searching for a reliable Melieva 2mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of critical cytotoxic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that life-saving oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Melieva 2mg? Melieva 2mg is an oral antineoplastic therapy containing the active pharmaceutical ingredient Melphalan. Manufactured by Allieva Pharma Pvt Ltd, this 2mg tablet belongs to the class of medications known as Alkylating Agents. It is a nitrogen mustard derivative specifically designed to treat cancers of the blood and bone marrow, serving as a pillar in hematological oncology for decades. 1. Therapeutic Indications Multiple Myeloma: Often used in combination with other agents (like Prednisone) for the palliative treatment of patients with multiple myeloma. Ovarian Adenocarcinoma: Indicated for the treatment of non-resectable epithelial ovarian cancer. Polycythemia Vera: Utilized to control the overproduction of red blood cells in specific patient cases. Advanced Breast Cancer: Occasionally used in palliative protocols for advanced stages of the disease. Conditioning Therapy: In higher dose protocols, it is used as a conditioning treatment before bone marrow or stem cell transplants. 2. Mechanism of Action: DNA Cross-Linking Alkylation of DNA: The medication attaches an alkyl group to the DNA of cancer cells. Interstrand Cross-linking: It creates chemical bonds between the two strands of the DNA double helix. Inhibition of Replication: By “locking“ the DNA strands together, the cancer cell can no longer replicate its genetic material or repair itself. Cell Cycle Non-Specific: Unlike some therapies, Melphalan can attack cancer cells at various stages of their growth cycle, leading to effective tumor mass reduction. 3. Administration and Dosage Management Standard Dosing: Dosage is highly individualized based on the patient's body surface area (BSA) and blood counts. Administration: It is generally recommended to take Melieva on an empty stomach (1 hour before or 2 hours after meals) to ensure consistent absorption. Handling: As a potent cytotoxic drug, the tablets should not be crushed or broken. Caregivers should handle the medication with caution. Clinical Side Effects & Safety Monitoring Bone Marrow Suppression: The primary side effect is a decrease in white blood cells (leukopenia) and platelets (thrombocytopenia). Frequent blood counts are mandatory. Gastrointestinal Health: Potential for nausea, vomiting, and mouth sores (mucositis). Secondary Malignancies: Long-term use of alkylating agents has been associated with an increased risk of secondary leukemias. Pulmonary Monitoring: Rare cases of pulmonary fibrosis have been reported; patients should report any persistent cough or breathing difficulties. Renal Function: Patients with impaired kidney function require careful dose adjustment to avoid toxicity. Why Source Melieva 2mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Melieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Lenakast 25mg Capsule (Lenalidomide): Comprehensive Clinical Profile & Global Supply Guide Lenakast 25mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. As a structural analogue of thalidomide, Lenakast 25mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Manufactured by Aprazer Healthcare, Lenakast is a trusted choice for oncology centers worldwide. Therapeutic Indications and Clinical Usage Lenakast 25mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Lenakast 25mg Works Lenakast exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-α and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For multiple myeloma, the standard dose is 25 mg taken orally once daily on Days 1–21, followed by a 7-day rest period. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lenakast 25mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. If counts drop too low, a dose reduction or temporary pause is usually implemented. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Lenakast. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care, adequate hydration, and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should wear gloves if handling the capsules directly to avoid accidental skin exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ WHO-GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Pomcad 4 mg Capsule: Understanding Pomalidomide for Multiple Myeloma Treatment Description: Learn about Pomcad 4 mg Capsule (Pomalidomide). Discover its role in treating relapsed and refractory multiple myeloma, including clinical indications, dosing, and safety precautions. Pomcad 4mg Capsule: Essential Insights into Pomalidomide Therapy for Multiple Myeloma Product Profile: Understanding Pomcad 4mg Capsule Pomcad 4mg Capsule contains Pomalidomide, an immunomodulatory agent used primarily in the treatment of multiple myeloma. It is typically prescribed for patients who have previously undergone at least two lines of therapy, including lenalidomide and a proteasome inhibitor, and whose disease has progressed. 1. Clinical Indications & Usage Relapsed/Refractory Multiple Myeloma: Used in combination with dexamethasone for adults whose cancer has not responded to or has worsened after previous standard treatments. Kaposi Sarcoma: Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma who have failed highly active antiretroviral therapy (HAART), as well as for those with HIV-negative Kaposi sarcoma. 2. Mechanism of Action Immunomodulation: Enhances the body’s immune system response to better identify and destroy malignant plasma cells. Direct Anti-Tumor Activity: Directly inhibits the proliferation of myeloma cells, disrupting their growth cycle. Anti-Angiogenic Effect: Suppresses the development of new blood vessels that tumors require for growth and survival. Bone Marrow Microenvironment: Reduces inflammation within the bone marrow, creating an environment that inhibits cancer cell survival. 3. Administration and Dosing Guide Dosage: The standard dose for multiple myeloma is 4mg taken orally once daily. Cycle: Treatment is typically administered on days 1 through 21 of a 28-day cycle, repeated as directed by your physician. Administration: The capsule should be swallowed whole with water. Do not break, chew, or crush it. It can be taken with or without food, but should be taken at the same time each day. Missing a Dose: If a dose is missed, take it as soon as possible, provided it is not almost time for your next dose. Do not double the dose. ⚠️ Safety, Side Effects, and Monitoring Common Side Effects: Fatigue, nausea, diarrhea, constipation, fever, and decreased appetite. Hematologic Monitoring: Regular blood tests are essential to monitor for low white blood cell counts, anemia, and low platelet counts, which may increase infection and bleeding risks. Thromboembolism: There is an increased risk of blood clots. Healthcare providers may prescribe prophylactic blood-thinning medications. Skin Sensitivities: Patients may experience increased skin sensitivity to sunlight. 📦 Storage and Handling Specifications Temperature: Store in a closed container at room temperature (below 30°C). Protection: Keep away from moisture, heat, and direct light. Safety: Keep out of reach of children. If a capsule is accidentally broken or opened, avoid direct skin contact. 📄 Regulatory and Compliance Documentation Restricted Distribution Certification. Regulatory Compliance WHY CHOOSE ERNEST ONCOLOGY? Global Distribution Excellence Quality & Integrity Specialized Logistics PRESCRIPTION MEDICINE IS : YES Disclaimer: This product is a strictly regulated prescription medication and must be used under the direct supervision of a licensed oncologist or healthcare professional. This content is provided for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. 📞 Contact Ernest Oncology — Pharmaceuticals Medicine Exporter (Group of Ernest Pharmaceutical Pvt. Ltd.) 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Order Here: https://wa.me/919359902383

Thalidomide 100mg Capsule: Immunomodulatory and Anti-Angiogenic Therapy for Multiple Myeloma and ENL Are you searching for a reliable Thalidomide 100mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted immunomodulatory agents. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Thalidomide 100mg? Thalidomide 100mg is an oral therapeutic agent containing the active pharmaceutical ingredient Thalidomide. Once known primarily for other uses, it has been repurposed as a powerful Immunomodulatory Drug (IMiD). It is a cornerstone in the treatment of plasma cell dyscrasias and specific inflammatory conditions. Due to its potent nature, it is distributed under strict regulatory oversight to ensure patient safety and therapeutic efficacy. 1. Therapeutic Indications Multiple Myeloma: Used in combination with Dexamethasone for patients with newly diagnosed multiple myeloma. It is also utilized in relapsed or refractory cases. Erythema Nodosum Leprosum (ENL): An essential treatment for the cutaneous manifestations of moderate to severe ENL (a complication of leprosy). It is also used as maintenance therapy to prevent and limit the recurrence of skin lesions. Off-Label Oncology Use: Occasionally utilized in research-backed protocols for specific solid tumors and myelodysplastic syndromes where anti-angiogenic properties are required. 2. Mechanism of Action: Multi-Faceted Attack Immunomodulation: It alters the production of cytokines, specifically inhibiting Tumor Necrosis Factor-alpha (TNF-α), which is a key driver of inflammation and cancer cell survival. Anti-Angiogenesis: It blocks the formation of new blood vessels (angiogenesis) by interfering with growth factors like VEGF and bFGF. This effectively “starves“ tumors of the nutrients needed to expand. Direct Anti-Tumor Effect: It induces cell cycle arrest and apoptosis (programmed cell death) in malignant plasma cells by disrupting their interaction with the bone marrow microenvironment. 3. Administration and Dosing Management Standard Dosing: For Multiple Myeloma, the typical dose ranges from 100mg to 200mg daily. For ENL, dosing is adjusted based on the severity of the reaction. Timing: It is generally recommended to take the capsule once daily at bedtime, at least 1 hour after the evening meal, to minimize sedation. Safety Handling: Capsules must be swallowed whole. Healthcare providers and caregivers should handle the medication with caution; direct contact with the powder inside the capsule should be avoided. Clinical Side Effects & Safety Monitoring eratogenicity (Birth Defects): This is the most critical risk. Thalidomide must never be used by pregnant women. Male and female patients must strictly adhere to specialized Risk Evaluation and Mitigation Strategies (REMS). Peripheral Neuropathy: Potential for tingling, numbness, or pain in the hands and feet. Early detection is vital to prevent permanent nerve damage. Venous Thromboembolism (VTE): Increased risk of blood clots (DVT or Pulmonary Embolism), especially when combined with steroids. Prophylactic blood thinners are often prescribed. Drowsiness & Sedation: Patients are advised to avoid heavy machinery or driving until their reaction to the drug is known. Why Source Thalidomide 100mg from Ernest Oncology? Verified Authenticity: Direct sourcing of high-integrity Thalidomide with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Lenalieva 5mg Capsule: Precision Immunomodulatory Therapy for Global Hematology Sourcing Are you searching for a verified Lenalieva 5mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced hematology medications. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical immunomodulatory treatments reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Lenalieva 5mg? Lenalieva 5mg is an oral targeted therapy containing the active pharmaceutical ingredient Lenalidomide. Manufactured by Allieva, this 5mg capsule belongs to a class of medications known as immunomodulatory agents (IMiDs). It is a cornerstone in the treatment of various plasma cell dyscrasias and certain blood disorders, offering a multi-pathway approach to halting cancer progression. 1. Therapeutic Indications Multiple Myeloma (MM): Used in combination with Dexamethasone for patients who have received at least one prior therapy, and as a maintenance therapy following autologous stem cell transplantation. Myelodysplastic Syndromes (MDS): Specifically for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): For patients whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib. Follicular Lymphoma & Marginal Zone Lymphoma: In combination with Rituximab for previously treated adult patients. 2. Mechanism of Action: The Three-Tiered Defense Immune System Stimulation: It enhances the activation of T-cells and Natural Killer (NK) cells, significantly improving the body’s innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It inhibits the growth of new blood vessels (angiogenesis) within the bone marrow, effectively “starving“ the tumor of the nutrients and oxygen it needs to expand. Direct Tumor Suppression: It binds directly to the Cereblon E3 ubiquitin ligase complex, leading to the degradation of essential transcription factors (Aiolos and Ikaros) required for the survival of B-cell malignancies. 3. Administration and Dosing Cycle Management: Often prescribed in a 28-day cycle (e.g., 21 days on, 7 days off). Timing: The capsule should be taken at approximately the same time each day, with or without food. Handling: Capsules must be swallowed whole. They should not be opened, broken, or chewed. Clinical Side Effects & Safety Monitoring Hematological Toxicity: Significant risk of Neutropenia (low white blood cells) and Thrombocytopenia (low platelets). Weekly blood counts are typically required during the first several cycles. Venous Thromboembolism: Increased risk of deep vein thrombosis (DVT) and pulmonary embolism. Prophylactic anticoagulation is often recommended. Teratogenicity: CRITICAL WARNING: Lenalidomide is structurally related to thalidomide and can cause severe, life-threatening birth defects. Strict adherence to a regulated pregnancy prevention program is mandatory. Gastrointestinal: Diarrhea, constipation, nausea, and abdominal pain. General: Fatigue, muscle cramps, and skin rashes. Why Source Lenalieva 5mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Lenalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and comprehensive B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Pomalid 4mg Capsule: Understanding Pomalidomide for Multiple Myeloma Description: Discover comprehensive information about Pomalid 4mg Capsule (Pomalidomide). Learn about its clinical uses in multiple myeloma, mechanism of action, dosing guidelines, and vital safety precautions for patients. Pomalid 4mg Capsule: Essential Insights into Pomalidomide Therapy for Blood Cancer. Product Profile: Understanding Pomalid 4mg Capsule Pomalid 4mg Capsule (Pomalidomide) is a potent immunomodulatory medication primarily used to treat multiple myeloma, a cancer of the plasma cells in the bone marrow. It is often prescribed for patients who have previously undergone multiple lines of therapy and whose disease has continued to progress. 1. Clinical Indications & Usage Relapsed/Refractory Multiple Myeloma: Treatment for adult patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression. Combination Therapy: It is typically administered in combination with dexamethasone to enhance its therapeutic effectiveness. 2. Mechanism of Action Immune Activation: Enhances the proliferation and functional capacity of T-lymphocytes and Natural Killer (NK) cells to target cancer cells. Angiogenesis Inhibition: Obstructs the formation of new blood vessels required by tumor cells to grow and survive. Induction of Apoptosis: Initiates programmed cell death within myeloma cells to reduce tumor bulk. Cytokine Modulation: Regulates the synthesis of key cytokines to disrupt the immunosuppressive environment created by malignancies. 3. Administration and Dosing Guide Standard Dose: The recommended dose is 4 mg taken orally once daily. Cycle: Treatment is typically administered on Days 1 through 21 of repeated 28-day cycles. Consistency: Take the capsule at the same time each day, either with or without food. Missed Doses: If a dose is missed, it may be taken within 12 hours of the scheduled time. If more than 12 hours have passed, skip the missed dose and resume your regular schedule. Never double the dose. ⚠️ Safety, Side Effects, and Monitoring Common Side Effects: Fatigue, nausea, diarrhea, constipation, fever, and coughing. Hematologic Monitoring: Regular blood tests are critical to monitor for neutropenia (low white blood cell count) and thrombocytopenia (low platelet count), which increase the risk of infection and bleeding. Blood Clot Risk: There is an increased risk of thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism). Pregnancy Warning: Pomalidomide is strictly contraindicated during pregnancy due to the risk of severe birth defects. Both male and female patients must use effective contraception as directed by their physician. 📦 Storage and Handling Specifications Temperature: Store in a cool, dry place at or below 30°C. Protection: Keep the container tightly closed and protect it from direct sunlight and moisture. Safety Handling: If the capsule is accidentally opened or broken, avoid direct skin contact. If contact occurs, wash the area thoroughly with soap and water. Disposal: Keep out of reach of children and pets. 📄 Regulatory and Compliance Documentation Safety Programs Quality Verification Professional Distribution WHY CHOOSE ERNEST ONCOLOGY? Global Reach & Reliability Quality Assurance Specialized Logistics PRESCRIPTION MEDICINE IS :YES Disclaimer: This product is a strictly regulated prescription drug and must be administered under the supervision of a licensed oncologist or healthcare professional. This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult your physician for medical guidance. 📞 Contact Ernest Oncology —Pharmaceutical Medicine Exporter (Group of Ernest Pharmaceutical Pvt. Ltd.) 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Order Here: https://wa.me/919359902383

Pomalid 4mg Capsules: Targeted Therapy for Multiple Myeloma Description: Discover essential information on Pomalid 4mg capsules. Learn about its use in multiple myeloma, administration, safety protocols, and how to source high-quality oncology medications through Ernest Oncology. Headline: Pomalid 4mg Capsules: Clinical Insights and Patient Safety Guidelines Understanding Pomalid 4mg Capsules Pomalid 4mg capsules are a specialized immunomodulatory medication primarily indicated for the treatment of Multiple Myeloma, a cancer of the plasma cells in the bone marrow. This therapy is often prescribed in combination with other agents, such as dexamethasone, to help manage the disease by targeting abnormal cells and supporting the body’s natural immune response. 1. Clinical Indications & Usage Pomalid is indicated for patients who have previously received other standard treatments for multiple myeloma, including lenalidomide and a proteasome inhibitor, and whose disease has demonstrated progression during or within 60 days of completing the last therapy. It is an oral medication designed to stabilize the condition and extend progression-free survival. 2. Mechanism of Action Targeted Degradation: It binds to the cereblon (CRBN) protein, triggering the ubiquitination and degradation of specific transcription factors (Ikaros and Aiolos) essential for myeloma cell survival. Immune System Activation: It enhances the proliferation and activation of T-cells and Natural Killer (NK) cells to better identify and eliminate malignant cells. Anti-Angiogenic Activity: It inhibits the formation of new blood vessels that provide the necessary nutrients and oxygen for tumor growth. Induction of Apoptosis: It initiates programmed cell death within myeloma cells and disrupts the protective interactions between these cells and the bone marrow microenvironment. 3. Administration and Dosing Guide Dosage: The standard dose is 4 mg taken orally once daily. Cycle: It is typically administered on Days 1 to 21 of each 28-day cycle. Instructions: Capsules should be swallowed whole with water. They may be taken with or without food but should be taken at the same time each day to maintain consistent blood levels. Missed Doses: If a dose is missed, patients should not take two doses at once; they should wait until their next scheduled time. ⚠️ Safety, Side Effects, and Monitoring Common Side Effects: Fatigue, nausea, diarrhea, constipation, back pain, and decreased appetite. Blood Cell Impacts: Pomalid may lower white blood cell, red blood cell, and platelet counts, increasing the risk of infections, anemia, and bruising. Regular blood counts are essential. Severe Risks: It carries significant risks for fetal harm; therefore, strict pregnancy prevention programs must be followed by both men and women. There is also a risk of blood clots (venous thromboembolism). Monitoring: Regular medical check-ups, blood tests (for blood count and liver/kidney function), and monitoring for signs of infection or respiratory issues are vital. 📦 Storage and Handling Specifications Temperature: Store at controlled room temperature (typically 20°C to 25°C). Safety: Keep out of reach of children and pets. Store in a secure, dry place. Handling: Because the drug can be absorbed through the skin, capsules should not be opened, crushed, or broken. If a capsule is damaged, avoid inhaling the powder and wash the area thoroughly with soap and water. 📄 Regulatory and Compliance Documentation GMP Certification International Standards Import Compliance Pharmacovigilance WHY CHOOSE ERNEST ONCOLOGY? Global Reliability Quality Assurance Dedicated Logistics PRESCRIPTION MEDICINE: YES Disclaimer: This information is for educational purposes only and does not constitute medical advice. Pomalidomide is a prescription medication that must only be used under the strict supervision of a qualified oncologist or healthcare professional. Always consult your doctor before starting any new medication. Use of this drug requires adherence to a mandatory pregnancy prevention program. Contact Ernest Oncology—Pharmaceutical Medicine Exporter (GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.) Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com Email: exports@ernestpharmaceuticals.com Business Type: Exporter | Bulk Supplier | Distributor WhatsApp: +91 93599 02383 WhatsApp Link: https://wa.me/919359902383